Skip to content

HIV needs many more mutations to acquire resistance to darunavir

TMC125 study highlights risk of staying on failing NNRTI regimen

US researchers estimate HIV treatment will work for 24 years and cost £200k

Genetically modified HIV shows early promise as a gene therapy viral vector

Darunavir response did not differ by prior PI in POWER studies

MK-0518: three-quarters of highly treated patients have undetectable viral load at 24 weeks

Tibotec announces expanded access programme for new NNRTI TMC125

Draft BHIVA treatment guidelines: respond by Monday September 4th

Vicriviroc effective in treatment-experienced patients, but malignancy questions remain unanswered